Interferon-gamma (IFN-gamma) production pathway (IFN-gamma pathway)

The Interferon-gamma (IFN-gamma) production pathway is a central axis of the immune system, primarily orchestrated by Th1 cells, CD8+ cytotoxic T cells, and natural killer (NK) cells (Schoenborn & Wilson, 2007, Advances in Immunology). This pathway is initiated by the action of inducing cytokines such as interleukin-12 (IL-12) and interleukin-18 (IL-18), which trigger intracellular signaling through Janus kinases (JAK1 and JAK2) and Signal Transducers and Activators of Transcription (STATs), particularly STAT1 and STAT4 (Rawlings et al., 2004, Journal of Cell Science). IFN-gamma serves as the primary activator of macrophages, enhances antigen presentation via MHC molecules, and promotes the differentiation of T cells toward a pro-inflammatory phenotype. Dysregulation of this pathway, characterized by excessive IFN-gamma production, is a hallmark of several severe inflammatory and autoimmune conditions, including hemophagocytic lymphohistiocytosis (HLH) and systemic lupus erythematosus (Locatelli et al., 2020, NEJM). Conversely, the pathway is essential for host defense against intracellular pathogens and plays a significant role in anti-tumor immunity. Therapeutic interventions targeting this pathway include monoclonal antibodies that neutralize IFN-gamma directly, such as emapalumab, or inhibitors of upstream cytokines and downstream signaling molecules like JAK inhibitors (FDA, 2018).

Other names

IFN-gamma signaling pathwayType II interferon production pathwayInterferon-gamma induction pathwayIFNG pathway

Modulation of the pathway occurs through direct neutralization of the IFN-gamma cytokine, blockade of upstream inducing cytokines like IL-12 and IL-18, or inhibition of downstream signaling components such as JAK1 and JAK2.